1. Characteristic 1: compound with formula structure (1) or acceptable salt of medicine with formula structure, where x is O, s or CH2； B is natural or unnatural purification or pyridine group； or B is selected from a group of residual formulas (2)；This is N-C (R19) -；R1 is h, or other part of formula group (3)；R2 is h, or other formula (4),O R1 and R2 are combined into a formula group (5)；R 3 is C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 3-7 cycloalkyl； each of R4, R5, R7 and R8 is independently H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, -OR20, -SR20 or -N (R20) 2； each of R6, R9, R10, R11 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 5 or 6 membered monocyclic heteroaryl, 9 or 10 bicyclic heteroaryl members, halo, -OR20, -SR20, -S (O) R20, -S (O) 2R20, -S (O) 2N (R20) 2, -NHC (O) OR20, -NHC (O) N (R20 ) 2, C1-6 haloalkyl, C1-6 hydroxyalkyl, -O- (C1-6 haloalkyl),-Cn, - no, - n (R20) 2, - NH (C1-6 tar) - 5 or 6 list periodic heterosexuals,-NH (C1-6 tar) - (9 or 10 heterocycles)-C (O) R20, -C (O) OR20, -C (O) N (R20) 2 and -NHC (O) R20, wherein said C2-6 alkenyl group and said C2-6 alkynyl group may be optionally substituted with a halo group； R12 is H or - (C1-6 alkylene) -T-R21； R13 is H or - (C1-6 alkylene) -T-R21, or R12 and R13 can be joined to form a C2-4 alkylene group between the oxygen atoms to which R12 and R13 are attached, in which said alkylene group C2-4 is substituted with at least one C6-10 aryl group； R14 is H, C6-10 aryl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered bicyclic heteroaryl, wherein said C6-10 aryl group,said 5 or 6 membered monocyclic heteroaryl group and said 9 or 10 membered bicyclic heteroaryl group may be optionally substituted with R22； R15 is H, C1-6 alkyl, C3-7 cycloalkyl, phenyl or benzyl, wherein said C1-6 alkyl may be optionally substituted with a group selected from halo, -OR20, -SR20, guanidino, -N (R20) 2, -C (O)
